发明名称 |
Diagnostic marker for effect of anticancer agent |
摘要 |
The present invention enables to realize a convenient determination of a therapeutic effect of an anticancer agent on a cancer. Specifically, the present invention provides a diagnostic marker for an effect of an anticancer agent on a cancer, comprising a substance having an affinity for a fragment of an extracellular domain of c-MET; a diagnostic reagent for an effect of an anticancer agent on a cancer, comprising a substance having an affinity for a fragment of an extracellular domain of c-MET and the fragment of the extracellular domain of c-MET; and a method of testing an effect of an anticancer agent on a cancer, comprising (a) measuring a concentration of a fragment of an extracellular domain of c-MET in a biological sample from a subject, and (b) comparing the measured concentration of the fragment of the extracellular domain of c-MET with an indicator which presents a relationship between a concentration of the fragment of the extracellular domain of c-MET and the effect of the anticancer agent on the cancer. |
申请公布号 |
US9175084(B2) |
申请公布日期 |
2015.11.03 |
申请号 |
US201113635911 |
申请日期 |
2011.03.18 |
申请人 |
FUJIREBIO INC. |
发明人 |
Ise Nobuyuki;Nambara Daisuke;Omi Kazuya |
分类号 |
A61K35/12;C07K16/28;G01N33/50;G01N33/574;C12Q1/48;G01N33/566 |
主分类号 |
A61K35/12 |
代理机构 |
Oblon, McClelland, Maier & Neustadt, L.L.P. |
代理人 |
Oblon, McClelland, Maier & Neustadt, L.L.P. |
主权项 |
1. A method for selecting and treating a subject having a lung cancer sensitive to a c-MET inhibitor comprising:
detecting a secreted fragment of a c-MET extracellular domain in a cell-free portion of a biological sample obtained from the subject having a lung cancer that is EGFR-inhibitor resistant using an antibody or an antigen-binding fragment thereof that binds to c-MET alpha chain of a c-MET extracellular domain, selecting a subject having a lung cancer sensitive to treatment with a c-MET inhibitor when said secreted fragment of the c-MET extracellular domain is detected, and treating the subject with a c-MET inhibitor selected from the group consisting of PHA-665752, SU11274, XL-880, XL-184, ARQ197, AMG208, AMG458, CD-355621, and MP470. |
地址 |
Tokyo JP |